RE:RE:RE:Be wary of analysts (some) | Cormark Securities Inc. | David Dean, MSc, MBA | 416-943-6397 |
| Euro Pacific Canada | Douglas Loe, Ph.D MBA | 416 775-1004 |
| Zacks Investment Research | Jason Napodano, CFA | 312-265-9421 |
https://www.cipherpharma.com/Investor-Relations/Analyst-Coverage/default.aspx
Lipofen
- U.S. commercial launch in 2007
- Marketed by Kowa Pharmaceuticals America
During 2013, Lipofen prescriptions decreased slightly (5%) but the product maintained a market share of 1.5% of the total fibrate market. Cipher's U.S. marketing partner for Lipofen® continues to promote the product in a second detail position. ConZip® - U.S. commercial launch in Q3 2011
- Marketed by Vertical Pharmaceuticals
Durela®
- Canadian commercial launch in Q1 2012
- Marketed by Medical Futures
Cipher's extended-release tramadol is marketed in the U.S. by Vertical Pharmaceuticals under the trade name ConZip®. In Q1 2013, Vertical expanded its sales force from 60 to 75 representatives, which has contributed to modestly improved performance. In Q4 2013, prescriptions grew 3% compared to Q4 2012. In late Q4 2013, Avista Capital Partners, a US-based private equity firm, acquired a controlling equity interest in Vertical with stated plans to invest in additional selling resources while maintaining current management. the three year is all products, it is great that one is generating most of the income thus the two others have slowed revenue but it is a true three year picture of growth from the companies books.
https://www.cipherpharma.com/Investor-Relations/News/news-details/2014/Cipher-reports-record-financial-results-for-2013/default.aspx